简要报告:抑制MATE-1的酪氨酸激酶抑制剂可导致肺癌患者肾功能「假性」下降
该研究系统分析了接受MATE-1抑制剂酪氨酸激酶抑制剂(TKI)治疗的致癌基因驱动肺癌患者,发现基于肌酐计算的肾小球滤过率(GFR)低于基于胱抑素C的计算值。在17例同时有肌酐和胱抑素C数据的患者中,15例胱抑素C计算的GFR更高。作者建议在肌酐升高时先用胱抑素C重新计算GFR,再考虑其他肾损伤病因及调整TKI治疗。
要点
- 863例接受MATEi TKI治疗的患者中,10%(90例)发生急性肾损伤,其中KDIGO 1期占72%(65例)。
- 17例同时有肌酐和胱抑素C数据者中,15例用胱抑素C计算的GFR高于肌酐计算值。
- 作者建议肌酐升高时先用胱抑素C重算GFR,再排查其他肾损伤病因及减停TKI。
核心结论
- 在接受MATEi TKI治疗的癌症患者中,几乎所有病例使用胱抑素C计算的GFR均高于使用肌酐计算值。
- 当接受MATE-1抑制剂的患者肌酐水平似乎升高时,作者建议先用胱抑素C重新计算GFR,再寻找其他肾损伤病因并减少或停止TKI治疗。
研究设计与样本
- 对接受多种MATEi TKI(brigatinib、cabozantinib、capmatinib、crizotinib、entrectinib、lorlatinib、pralsetinib、selpercatinib和tepotinib)治疗的致癌基因驱动肺癌患者进行肾功能不全的系统性分析,共纳入863例。
- 急性肾损伤按肌酐水平(KDIGO标准)分为1期(≥1.5倍但<2倍基线)、2期(≥2倍但<3倍基线)或3期(>3倍基线)。
- 在有条件时,使用不受MATE-1影响的肾功能标志物胱抑素C评估GFR。
主要发现
- 863例接受MATEi TKI治疗的患者包括crizotinib(39%,n=333)、lorlatinib(17%,n=144)、cabozantinib(10%,n=87)、selpercatinib(10%,n=82)、capmatinib(9%,n=77)、brigatinib(6%,n=53)、entrectinib(5%,n=45)、tepotinib(5%,n=41)和pralsetinib(0.1%,n=1)。
- 90例(10%)发生急性肾损伤的患者中,KDIGO 1、2、3期分别占72%(n=65)、21%(n=19)和7%(n=6)。
- 17例患者有TKI治疗期间同时采集的肌酐和胱抑素C水平,其中大多数(17例中15例)用胱抑素C计算的GFR高于用肌酐计算值。
- 在胱抑素C计算GFR高于肌酐计算值的15例患者中,差值<10 mL/min、10-19 mL/min、20-29 mL/min和≥30 mL/min者分别占27%(4/15)、20%(3/15)、20%(3/15)和33%(5/15)。
- 3例患者跨越3年的长期数据显示,在所有时间点中96%(51个时间点中49个)用胱抑素C计算的GFR高于肌酐计算值。
关键数值与推荐
- 急性肾损伤分期采用KDIGO标准:1期≥1.5倍但<2倍基线,2期≥2倍但<3倍基线,3期>3倍基线。
- 作者建议:接受MATE-1抑制剂的患者肌酐水平似乎升高时,先用胱抑素C重新计算GFR,再寻找其他肾损伤病因并减少或停止TKI治疗。
临床怎么用
- 对接受MATEi TKI治疗的肺癌患者,当肌酐升高疑似肾损伤时,作者建议先用胱抑素C重新计算GFR,再排查其他肾损伤病因及考虑减停TKI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Select tyrosine kinase inhibitors (TKIs) used to treat oncogene-driven lung cancers also inhibit MATE-1. When MATE-1 is blocked, creatinine is retained in the serum. Elevated creatinine levels raise the specter of drug-induced intrarenal insufficiency despite the lack of true renal injury. We conducted a systematic analysis of MATE-1 inhibitor (MATEi)-treated patients to comprehensively characterize this phenomenon. METHODS: Patients with oncogene-driven lung cancer treated with a wide variety of MATEi TKIs (brigatinib, cabozantinib, capmatinib, crizotinib, entrectinib, lorlatinib, pralsetinib, selpercatinib, and tepotinib) were eligible for an analysis of renal dysfunction. Acute kidney injury was classified on the basis of creatinine levels (Kidney Disease: Improving Global Outcomes criteria) as stage 1 (≥1.5× but <2× baseline), stage 2 (≥2× but <3× baseline), or stage 3 (>3× baseline). When available, cystatin C, a marker of kidney function unaffected by MATE-1, was used to evaluate the glomerular filtration rate (GFR). RESULTS: We identified 863 patients receiving MATEi TKIs including crizotinib (39%, n = 333), lorlatinib (17%, n = 144), cabozantinib (10%, n = 87), selpercatinib (10%, n = 82), capmatinib (9%, n = 77), brigatinib (6%, n = 53), entrectinib (5%, n = 45), tepotinib (5%, n = 41), and pralsetinib (0.1%, n = 1). Of the 90 patients (10%) with acute kidney injury, Kidney Disease: Improving Global Outcomes stages 1, 2, and 3 were observed in 72% (n = 65), 21% (n = 19), and 7% (n = 6) of patients, respectively. Concurrently drawn creatinine and cystatin C levels on TKI therapy were available for 17 patients. In most cases (n = 15 of 17), the calculated GFR was higher using cystatin C versus creatinine. The percentage of patients whose GFR was higher using cystatin C versus creatinine by less than 10 mL/min, 10 to 19 mL/min, 20 to 29 mL/min, and more than or equal to 30 mL/min was 27% (n = four of 15), 20% (n = three of 15), 20% (n = three of 15), and 33% (n = five of 15), respectively. Long-term data in three patients that spanned 3 years revealed that GFR was higher using cystatin C versus creatinine in 96% (n = 49 of 51) of all time points. Using a virtual clinical trial GFR cutoff of 40 mL/min, the percentage of eligible patients rose from 41% (n = seven of 17) using creatinine calculations to 71% (n = 12 of 17) using cystatin C calculations. CONCLUSIONS: The calculated GFR in patients with cancer receiving MATEi TKIs was higher in almost all cases when using cystatin C. When serum creatinine level seems elevated in patients receiving MATE-1 inhibitors, we recommend recalculating GFR using cystatin C before searching for other etiologies of kidney injury and reducing or stopping TKI therapy.
引用
- Chen MF, Harada G, Liu D, et al. Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function. J Thorac Oncol. 2023. PMID: 37748692. doi:10.1016/j.jtho.2023.09.1444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。